Title: Money Today-- LegoChem builds a "venture business - pharmaceutical company - clinic" model

Publication: Money Today/ Soo A Kim, Dong Hee Kim

Date: 16 October 2015

Summary

• CEO Yong Zu Kim met with investors and stockholders. He said, "The ultimate goal is to become a world-renowned research-based pharmaceutical company that can produce, sell, and market."

• He was criticized that he made a quick decision. However, he explained, "There was no reason to wait when we shared the same sentiment with Khanmed and we hoped to create a great synergy through this acquisition."

• CEO Yong Zu Kim said “We plan to secure our own brand in the medium to long term and to expand our portfolio of new medicine in the long term." In other words, the acqusition of Khanmed will complete the value chain of "venture business - pharmaceutical company - clinic."

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).